Evaluating the Effectiveness of Anti-β-Amyloid Therapies in Alzheimer's Disease
Author Information
Author(s): Manal Aljuhani, Ashraf Azhaar, Edison Paul
Primary Institution: Prince Sattam Bin Abdulaziz University
Hypothesis
What is the clinical meaningfulness of anti-β-amyloid therapies amidst concerns of amyloid-related imaging abnormalities in Alzheimer's disease?
Conclusion
Anti-β-amyloid therapies can slow cognitive decline in Alzheimer's disease but are associated with significant risks of adverse events.
Supporting Evidence
- Monoclonal antibodies against β-amyloid can slow clinical decline by 25-40%.
- Adverse events like amyloid-related imaging abnormalities can occur early in treatment.
- Clinical trials showed that lecanemab and donanemab received FDA approval based on their efficacy.
Takeaway
This study looks at how certain treatments for Alzheimer's disease can help people think better, but they can also cause some serious side effects.
Methodology
The review evaluates clinical trial results and safety concerns associated with anti-β-amyloid therapies.
Potential Biases
Potential biases may arise from unblinding and dropout rates in clinical trials.
Limitations
The study's findings may not be generalizable to all Alzheimer's patients due to the selective nature of clinical trial participants.
Participant Demographics
Participants included individuals with early Alzheimer's disease, with a focus on racial and ethnic diversity.
Statistical Information
P-Value
0.012
Confidence Interval
95% CI not specified
Statistical Significance
p=0.012
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website